Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
BeiGene Announces Updates to Commercial Leadership Team
From BeiGene, Ltd.
Via Business Wire
Top 2 Health Care Stocks That May Plunge In August
 
Via Benzinga
Evaluating BeiGene: Insights From 6 Financial Analysts
 
Via Benzinga
Innovent Bio hopes for plus-sized profits from obesity drug
Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allowing rival products to gain a market advantage The executive in charge of... 
Via Benzinga
Topics Retirement
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
UCB announced plans to divest its current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. It will sell this “mature” neurology and... 
Via Talk Markets
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
From BeiGene, Ltd.
Via Business Wire
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors for advanced gastric, gastroesophageal junction adenocarcinoma, and... 
Via Benzinga
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
From BeiGene
Via Business Wire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
Via Talk Markets
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
From BeiGene, Ltd.
Via Business Wire
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
The big pharma company's top drug is losing ground, but its dividend keeps rising. 
Via The Motley Fool
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
From BeiGene, Ltd.
Via Business Wire
Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio?
10 worst performing large-cap stocks last week: Walgreens, Floor & Decor, Moderna, Birkenstock, BeiGene, Pool Corp, JD.com, Ecopetrol, International Paper, Micron. 
Via Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for... 
Via Benzinga
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi... 
Via Talk Markets
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
7 Large-Cap Stocks That Can Jump 50% By 2025
It isn't easy to find large-cap stocks offering 50% upside but that's exactly what this list provides for investors. 
Via InvestorPlace
Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio?
10 worst-performing large-cap stocks last week. National Grid, James Hardie, KE Holdings, JD.Com, XP, Nordson, BeiGene, Lululemon, Walgreens, and Li Auto. 
Via Benzinga
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
Via Talk Markets
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
From BeiGene, Ltd.
Via Business Wire
BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024
BGNE stock results show that BeiGene beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
Last week's top performers included Vertiv Holdings, Tesla, Tyler Technologies, and Newmont Corporation. 
Via Benzinga
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
From BeiGene, Ltd.
Via Business Wire
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.